Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abnobaVISCUM A
- Development stage
- Unknown
- Lead developer
- Abnoba
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous, Intratumoral
01
Overview
abnobaVISCUM A is a biologic antineoplastic agent derived from mistletoe (*Viscum album*) grown on fir trees (*Abies alba*). Developed by abnoba GmbH and marketed in regions like South Korea by LB Abnoba, it is used as an adjuvant therapy for various malignant tumors. The extract contains bioactive compounds, primarily mistletoe lectins (ML I, II, and III) and viscotoxins. Mistletoe lectins function as Type II ribosome-inactivating proteins (RIPs), which inhibit protein synthesis and induce apoptosis in cancer cells. Additionally, the drug exerts immunomodulatory effects by stimulating the activity of natural killer (NK) cells, T-lymphocytes, and the release of cytokines, thereby enhancing the host's immune response against the tumor. It is typically administered via subcutaneous injection to improve quality of life and reduce the side effects of conventional oncological treatments.
- Brand names
- abnobaVISCUM AAbnoba Viscum A압노바비스쿰에이
- Other names
- Viscum album extractMistletoe extractAbies alba mistletoe extract
02
Targets
RibosomeCASP3 (Caspase-3)CASP9 (Caspase-9)CASP8 (Caspase-8)
Beyond the preview
Go deeper on abnobaVISCUM A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abnobaVISCUM A.